Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-553 in Healthy Volunteers and Psoriasis
NCT03145948Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-553 in psoriasis (6 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum observed plasma concentration at Day 1, Time to Cmax at Day 1 and 6 more. Started May 2017; status: terminated.
02
Drugs
ABBV-553
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03145948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145948.